NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). NAPOLI 3 was a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2023-10, Vol.402 (10409), p.1272-1281
Hauptverfasser:	Wainberg, Zev A, Melisi, Davide, Macarulla, Teresa, Pazo Cid, Roberto, Chandana, Sreenivasa R, De La Fouchardière, Christelle, Dean, Andrew, Kiss, Igor, Lee, Woo Jin, Goetze, Thorsten O, Van Cutsem, Eric, Paulson, A Scott, Bekaii-Saab, Tanios, Pant, Shubham, Hubner, Richard A, Xiao, Zhimin, Chen, Huanyu, Benzaghou, Fawzi, O'Reilly, Eileen M
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Adenocarcinoma Adenocarcinoma - drug therapy Albumins Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer therapies Chemotherapy Gemcitabine Humans Interactive systems Intravenous infusion Irinotecan Labels Malignancy Medical prognosis Metastases Metastasis Oncology Oxaliplatin Paclitaxel Pancreas Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Randomization Safety Survival Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!